{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:52:07Z","timestamp":1781949127610,"version":"3.54.5"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00535-026-02427-z","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T18:18:50Z","timestamp":1777141130000},"page":"1035-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to \u201cLetter to \u201cIncreasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis\u201d\u201d"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-7638","authenticated-orcid":false,"given":"Shintaro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2427_CR1","doi-asserted-by":"publisher","unstructured":"Dong B, Hou L. Letter to \u201cIncreasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis\u201d. J Gastroenterol. 2026. https:\/\/doi.org\/10.1007\/s00535-026-02378-5","DOI":"10.1007\/s00535-026-02378-5"},{"key":"2427_CR2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00535-025-02279-z","volume":"60","author":"S Akiyama","year":"2025","unstructured":"Akiyama S, Ito Y, Shiroyama M, et al. Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I-BRITE cohort study. J Gastroenterol. 2025;60:1259\u201371.","journal-title":"J Gastroenterol"},{"key":"2427_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/09691413241240564","volume":"31","author":"C Hamashima","year":"2024","unstructured":"Hamashima C, Takahashi H. Cancer screening programs in Japan: progress and challenges. J Med Screen. 2024;31:207\u201310.","journal-title":"J Med Screen"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02427-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02427-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02427-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:44:34Z","timestamp":1781948674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02427-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":3,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02427-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.A. has received lecture fees from Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., Pfizer Japan Inc., Gilead Sciences K.K., EA Pharma Co., Ltd., AbbVie GK, Mochida Pharmaceutical Co., Ltd., Viatris Pharmaceuticals Japan Inc., JIMRO Co., Ltd., KISSEI Pharmaceutical Co., Ltd., Sandoz K.K., Kyorin Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Olympus Corporation, Nippon Kayaku Co., Ltd., Bristol-Myers Squibb Company, and Zeria Pharmaceutical Co., Ltd., and research grants from Mochida Pharmaceutical Co., Ltd. K.T. has received lecture fees from EA Pharma Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., KISSEI Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, Viatris Pharmaceuticals Japan Inc., and Mochida Pharmaceutical Co., Ltd., and research grants from Eli Lilly. K.T. serves in leadership roles in the Japanese Society of Inflammatory Bowel Disease without receiving any financial compensation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}